• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Rivaroxaban superior to aspirin at reducing recurrent stroke in patients with embolic stroke of undetermined source and left ventricular dysfunction: (NAVIGATE ESUS Trial)

byYuchen DaiandMichael Pratte
October 28, 2021
in Cardiology, Emergency, Hematology, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Rivaroxaban was superior to aspirin in reducing recurrent stroke or systemic embolism among patients with recent embolic stroke of undetermined source and left ventricular dysfunction.

2. Further research evaluating the efficacy and safety of long-term anticoagulation to prevent cardiac embolism and subsequent stroke in patients with left ventricular dysfunction should be considered.

Evidence Rating Level: 1 (Excellent)

Study Rundown: A subset of patients diagnosed with embolic ischemic stroke lack an identifiable cause/source of the embolus, referred to as embolic strokes of undetermined source (ESUS). In patients with ESUS and left ventricular (LV) dysfunction, the efficacy of anticoagulation vs aspirin at reducing recurrent stroke is unknown. This post hoc exploratory analysis used data from the NAVIGATE ESUS trial to determine whether anticoagulation was superior to aspirin in reducing the risk of cardiac embolism and subsequent stroke in patients with ESUS and evidence of LV dysfunction (defined as moderate to severe global impairment in LV contractility and/or a regional wall motion abnormality on echocardiography). The main endpoint was a reduction in risk of recurrent stroke or systemic embolism where secondary outcomes included recurrent stroke, systemic embolism, myocardial infarction, or cardiovascular mortality during a median follow-up of 10.4 months. A Cox proportional hazards model was used to assess for treatment interaction and to estimate the hazard ratios. Among 7,213 participants from the NAVIGATE ESUS trial, 502 (7.1%) had evidence of LV dysfunction, where those assigned to rivaroxaban vs aspirin had a lower risk of recurrent stroke or systemic embolism compared to participants without LV dysfunction. These results suggested that rivaroxaban, a factor Xa inhibitor, was superior to aspirin in reducing recurrent stroke or systemic embolism among patients with recent ESUS and evidence of LV dysfunction. Further research evaluating the efficacy and safety of long-term anticoagulation to prevent cardiac embolism and subsequent stroke in patients with LV dysfunction should be considered. A limitation of this study was the exploratory nature of the analysis in the setting of a negative overall trial, where the study findings should be considered hypothesis generating.

Click to read the study in JAMA Neurology

Relevant Reading: Rivaroxaban for stroke prevention after embolic stroke of undetermined source

RELATED REPORTS

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

#VisualAbstract: Apixaban is Superior to Aspirin for Stroke Prevention in People with Subclinical Atrial Fibrillation

In-Depth [randomized clinical trial]: This post hoc exploratory analysis of data from NAVIGATE ESUS, a phase 3 randomized clinical trial, included 7,213 participants, 7,107 (98.5%) of which had a documented assessment of LV function. Eligible patients were 50 years or older with neuroimaging-confirmed ESUS before screening from December 2014 to September 2017 across 459 stroke recruitment centers in 31 countries. Participants were randomized to receive either 15 mg of rivaroxaban or 100 mg of aspirin once daily. In total, LV dysfunction was present in 502 participants (7.1%; mean [SD] age, 67 [10] years; 130 [26%] women). Among these patients, annualized primary event rates were 2.4% (95%CI, 1.1-5.4) in those assigned to rivaroxaban vs 6.5% (95%CI, 4.0-11.0) in those assigned aspirin. In 6,605 participants without LV dysfunction, rates were similar between those assigned to rivaroxaban (5.3%; 95%CI, 4.5-6.2) vs aspirin (4.5%; 95%CI, 3.8-5.3). Furthermore, patients with LV dysfunction assigned to rivaroxaban had a lower risk of the primary outcome (HR, 0.36; 95%CI, 0.14-0.93) compared to those on aspirin, in contrast to participants without LV dysfunction (HR, 1.16; 95%CI, 0.93-1.46; P for treatment interaction = .03), with similar findings for secondary outcomes.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspirindirect oral anticoagulant (DOAC)DOACdoacsembolic strokeembolic stroke of undetermined source (ESUS)
Previous Post

#VisualAbstract: Gemcitabine plus cisplatin improves overall survival compared to fluorouracil plus cisplatin in metastatic or recurrent nasopharyngeal carcinoma

Next Post

#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

RelatedReports

Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage
Cardiology

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

May 2, 2025
Stent type may not be related to adverse cardiac events after surgery
Cardiology

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

February 17, 2025
#VisualAbstract: Apixaban is Superior to Aspirin for Stroke Prevention in People with Subclinical Atrial Fibrillation
StudyGraphics

#VisualAbstract: Apixaban is Superior to Aspirin for Stroke Prevention in People with Subclinical Atrial Fibrillation

February 14, 2025
No significant increased risk of bladder cancer with pioglitazone use
Pharma

Direct oral anticoagulants have similar bleeding risk compared with aspirin

February 10, 2025
Next Post
#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

#VisualAbstract: Male sex and older age are independently associated with treatment failure after antibiotic treatment of community-acquired pneumonia

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Wellness Check: Exercise

#VisualAbstract Transplantation with omidubicel showed faster hematopoietic recovery and fewer early complications compared to standard myeloablative umbilical cord blood graft

#VisualAbstract Transplantation with omidubicel showed faster hematopoietic recovery and fewer early complications compared to standard myeloablative umbilical cord blood graft

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • Large language models show potential to provide feedback on research papers on a large-scale
  • #VisualAbstract: Elinzanetant Effectively Reduces Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.